Search Within

Jose T Baselga

Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. David Hyman (68)
  2. Maurizio Scaltriti (63)
  3. Clifford Hudis (57)
  4. Michael Berger (56)
  5. Larry Norton (51)
  6. Sarat Chandarlapaty (48)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific P13K inhibitor in combination with fulvestrant: Results from a phase I study
    Meeting Abstract

    Juric, D.; Gonzalez-Angulo, A. M.; Burris, H. A.; Schuler, M.; Schellens, J.; Berlin, J.; Gupta, A.; Seggewiss-Bernhardt, R.; Adamo, B.; Gil-Martin, M.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
    Meeting Abstract

    Montemurro, F.; Prat, A.; Rossi, V.; Valabrega, G.; Sperinde, J.; Peraldo-Neia, C.; Donadio, M.; Galvan, P.; Sapino, A.; Aglietta, M.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial
    Meeting Abstract

    Scaltriti, M.; Nuciforo, P.; Bradbury, I.; Sperinde, J.; Serra, V.; Parra, J. L.; Prudkin, L.; Harbeck, N.; Pusztai, L.; Ellis, C.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer
    Meeting Abstract

    Mayer, I. A.; Bardia, A.; Dickler, M. N.; Manning, H. C.; Mahmood, U.; Ulaner, G. A.; Hager, J. H.; Rix, P.; Zack, N.; Maneval, E. C.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neoadjuvant setting in the NeoALTTO trial
    Meeting Abstract

    Rimm, D. L.; Holmes, E.; Schalper, K.; Bradbury, I.; Zarrella, E.; Ellis, C.; Baselga, J.; Eidtmann, H.; Piccart, M.; Harbeck, N.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer
    Meeting Abstract

    Baselga, J.; Morales, S. M.; Awada, A.; Blum, J. L.; Tan, A. R.; Ewertz, M.; Cortes, J.; Moy, B.; Ruddy, K. J.; Haddad, T.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC)
    Meeting Abstract

    Isakoff, S. J.; Cruz, C.; Garber, J.; Lluch, A.; Fidalgo, J. A. P.; Tung, N.; Fernandez, C.; Kahatt, C.; Szyldergemajn, S.; Matos-Pita, A. S.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer - NeoPHOEBE
    Meeting Abstract

    Loi, S.; Loibl, S.; Di Cosimo, S.; Nekljudova, V.; Flamen, P.; Saini, K. S.; Michiels, S.; de la Pena, L.; Nanni, S.; Urban, P.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer
    Meeting Abstract

    Rugo, H. S.; Tredan, O.; Ro, J.; Morales, S. M.; Musolina, A.; Afonso, N.; Ferreira, M.; Park, K. H.; Cortes, J.; Tan, A. R.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2
    Meeting Abstract

    Yardley, D. A.; Hortobagyi, G. N.; Lebrun, F.; Beck, J. T.; Neven, P.; Baselga, J.; Petrakova, K.; Dakhil, S. R.; Sabatini, S.; Komorowski, A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save